A targeted treatment for IgA nephropathy at last?

(ERA-EDTA) Due to the immunological pathogenesis of IgA nephropathy, patients used to be given immunosuppressive therapy; however, this was shown to have no long-term benefit over optimal supportive therapy. Promising data from the interim analysis of a Phase II study with iptacopan now show that the targeted inhibition of a specific factor of the immune system allows a specific approach to therapy for IgAN without burdening patients with the severe side effects of immunosuppression.